Effects of Chardonnay Seed Flour on Vascular Health

  • Study type:

    Interventional What is this?

    Describes the nature of a clinical study. Types include:

    • Observational study — observes people and measures outcomes without affecting results.
    • Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
    • Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.

Study IDs

  • Site IRB:

    • Rochester, Minnesota: 13-007023
  • NCT ID:

    NCT02093455
  • Sponsor Protocol Number:

    13-007023

About this study

This is a randomized, double-blinded trial (Chardonnay seed flour vs. placebo - in pill form) with the purpose to test the impact of a four-month supplementation with Chardonnay Seed Flour (CSF) on endothelial function. Chardonnay flour is made from wine grape skins and seeds. We will examine the effect of CSF on parameters such as endothelial function (via EndoPAT testing), plasma lipid levels, glucose tolerance, insulin resistance, inflammatory markers, oxidative stress surrogates, endothelial progenitor cells (EPCs) as well as the makeup of and impact on the gut microbiome (via stool samples).

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.

See eligibility criteria

Inclusion Criteria:

  1. Age ≥18 years old
  2. Demonstrated endothelial dysfunction (EndoPAT score ≤ 2) at time of screening.

Exclusion criteria:

  1. Age below 18 or above 80
  2. Endothelial function greater than 2.0 at baseline
  3. Hypertension (at screening): any patient with systolic blood pressure (SBP ≥ 170 mmHg or diastolic blood pressure ≥ 110 mmHg, or hypotension (SBP < 100 mmHg
  4. Abnormal liver function tests
  5. Uncontrolled Diabetes Mellitus or the use of metformin for Diabetes Mellitus
  6. Difficulty swallowing capsules
  7. Gastrointestinal disease manifesting with symptoms of malabsorption such as celiac disease or Crohn's disease
  8. Non-English speakers
  9. Vulnerable populations unable to consent such as prisoners or dependents
  10. Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of the CSF including, but not limited to, any of the following:
    • History of major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy or bowel resection
    • Any history of pancreatic injury, pancreatitis or evidence of impaired pancreatic function/injury as indicated by abnormal lipase or amylase
    • Evidence of hepatic disease as determined by a history of hepatic encephalopathy, a history of cirrhosis, esophageal varices, or a history of portocaval shunt.
  11. History of hypersensitivity to any of the study supplement or suspected contraindications to the study supplement.
  12. History of noncompliance to medical regimens or unwillingness to comply with the study protocol

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Amir Lerman, M.D.

Contact us for the latest status

Katlyn Koepp

(507)255-2200

Koepp.Katlyn@mayo.edu